BiotechTube

Efungumab (Mycograb) + placebo + Amphotericin B + 5 flucytosine

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cryptococcal Meningitis

Conditions

Cryptococcal Meningitis

Trial Timeline

Aug 1, 2006 → —

NCT ID
NCT00847678

About Efungumab (Mycograb) + placebo + Amphotericin B + 5 flucytosine

Efungumab (Mycograb) + placebo + Amphotericin B + 5 flucytosine is a phase 2 stage product being developed by Novartis for Cryptococcal Meningitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00847678. Target conditions include Cryptococcal Meningitis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00847678Phase 2Terminated

Competing Products

18 competing products in Cryptococcal Meningitis

See all competitors
ProductCompanyStageHype Score
Mycograb + placeboNovartisPhase 2
52
Single dose liposomal Amphotericin and Fluconazole + FluconazoleGilead SciencesPhase 2/3
64
FluconazolePfizerPre-clinical
22
FluconazolePfizerPre-clinical
22
Fluconazole + Amphotericin BPfizerPre-clinical
22
Flucytosine + FluconazolePfizerPre-clinical
22
Fluconazole + Amphotericin BPfizerPre-clinical
22
Flucytosine + Fluconazole + Amphotericin BPfizerPre-clinical
22
FluconazolePfizerPre-clinical
22
FluconazolePfizerPre-clinical
22
Fluconazole + Amphotericin BPfizerPhase 3
76
Flucytosine + Fluconazole + Amphotericin BPfizerPre-clinical
22
FluconazolePfizerPre-clinical
22
Lobradimil + Amphotericin BAlkermesPhase 1
30
Flucytosine and fluconazole + FluconazoleBausch HealthPhase 2
47
MAT2203 + Amphotericin BMatinas BiopharmaPhase 1/2
33
Encochleated Amphotericin BMatinas BiopharmaPhase 1/2
33
MAT2203 + Amphotericin BMatinas BiopharmaPhase 3
69

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85